Regulatory Affairs Professionals Society (@RAPSorg) header
Regulatory Affairs Professionals Society (@RAPSorg) profile picture

The Regulatory Affairs Professionals Society (RAPS) is an international membership organization of regulatory professionals in the healthcare products sector.

Rockville, MD, USA
Joined February 2010
Photo by Regulatory Affairs Professionals Society (@RAPSorg)Photo by Regulatory Affairs Professionals Society (@RAPSorg)Photo by Regulatory Affairs Professionals Society (@RAPSorg)Photo by Regulatory Affairs Professionals Society (@RAPSorg)Photo by Regulatory Affairs Professionals Society (@RAPSorg)Photo by Regulatory Affairs Professionals Society (@RAPSorg)Photo by Regulatory Affairs Professionals Society (@RAPSorg)Photo by Regulatory Affairs Professionals Society (@RAPSorg)Photo by Regulatory Affairs Professionals Society (@RAPSorg)Photo by Regulatory Affairs Professionals Society (@RAPSorg)
The FDA recently issued warning letters to three manufacturers of active pharmaceutical ingredients based in China. hubs.ly/Q04FlxSc0
95
The FDA has issued draft guidance to assist sponsors in developing early-phase first-in-human studies for investigational drugs and biologics aimed at treating solid tumors as part of Operation TrialBlazer. hubs.la/Q04F4ZMt0
173
More than 500 comments have been submitted in response to the FDA discussion paper on generative AI (genAI)-enabled medical devices, and stakeholders have offered the agency a wide variety of advice on the best way to regulate these technologies. hubs.la/Q04DfhV70
3
1
189
The Department of Health and Human Services has announced that it will not take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians that compound six unapproved peptide bulk drug substances. hubs.la/Q04CSkrv0
191
An expert and officials from FDA offered tips for de novo classification requests and reviewed some of the changes related to de novos being proposed under the Medical Device User Fee Amendments (MDUFA VI) program at The MedTech Conference last week. hubs.la/Q04CzrDS0
1
1
232
FDA on Tuesday issued draft guidance laying out its proposed regulatory approach to overseeing individualized gene editing products, including those that feature multiple product variants developed under a single investigational new drug application. hubs.la/Q04Czr130
1
1
1
179
Acting US FDA Commissioner Kyle Diamantas touted the agency’s new rare disease framework as the best mechanism for modernizing rare disease development and incorporating the patient voice into scientific reviews for orphan therapies. hubs.la/Q04Cs3330
2
1
4
306
There needs to be a cultural shift to foster trust between regulators and the medtech industry when developing real-world evidence to support the marketing of medical devices, according to experts who spoke at The MedTech Conference on Monday. hubs.la/Q04CgKvh0
2
2
261
Major pharmaceutical companies are urging the FDA to adopt a more flexible, risk-based approach in its guidance on testing container-closure systems for drugs and biological products, especially when established materials and technologies are used. hubs.la/Q04C7mhF0
222
Top FDA medical device officials said they are focused on restaffing after last year’s reduction-in-force and are optimistic about the Medical Device User Fee Amendments agreement during a town hall panel at The MedTech Conference. hubs.la/Q04C7g4r0
2
4
286